How Will GlaxoSmithKline's Triple Therapy Combination Perform In The Market?
In the long term forecasts that GlaxoSmithKline (GSK) has shared with the street they assume that their respiratory sales in 2020 will be at least at the same level as in 2015 (GBP 5.5 billion).
In my previous article I have estimated the amount of erosion in respiratory sales that GSK will face on account of generic competition for its largest selling respiratory drug - Advair. The respiratory business sales could be wiped off by 50 percent on account of Advair generics. The respiratory business constitutes 40 percent of GSK's overall pharmaceutical revenues and hence it is important to understand whether or not GSK is in a good enough position to achieve the shared forecast.
The key drugs in the respiratory therapy area.. Read More